

Marco Del Chiaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2209997/publications.pdf>

Version: 2024-02-01

109
papers

6,652
citations

136950

32
h-index

66911

78
g-index

111
all docs

111
docs citations

111
times ranked

6229
citing authors

#	ARTICLE	IF	CITATIONS
1	Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2023, 30, 133-143.	2.6	7
2	New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 725-731.	2.6	24
3	Prognosis Based Definition of Resectability in Pancreatic Cancer. <i>Annals of Surgery</i> , 2022, 275, 175-181.	4.2	46
4	Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1013-1026.	7.0	19
5	Total pancreatectomy as an alternative to high-risk pancreatojejunostomy after pancreatoduodenectomy: a propensity score analysis on surgical outcome and quality of life. <i>Hpb</i> , 2022, 24, 1261-1270.	0.3	15
6	Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. <i>British Journal of Surgery</i> , 2022, 109, 450-454.	0.3	13
7	Lumen apposing metal stents vs double pigtail plastic stents for the drainage of pancreatic walled-off necrosis. <i>Minerva Gastroenterology</i> , 2022, , .	0.5	2
8	Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 617-622.	0.3	11
9	The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. <i>Pancreatology</i> , 2022, , .	1.1	1
10	Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?. <i>European Radiology</i> , 2022, 32, 5144-5155.	4.5	5
11	Controversial Role of Adjuvant Therapy in Node-Negative Invasive Intraductal Papillary Mucinous Neoplasm. <i>Annals of Surgical Oncology</i> , 2021, 28, 1533-1542.	1.5	20
12	Surgical Outcomes After Total Pancreatectomy: A High-Volume Center Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 1543-1551.	1.5	29
13	Commentary on: Divestment or skeletonization of the SMA or the hepatic artery for locally advanced pancreatic ductal cancer after neoadjuvant therapy. <i>Surgery</i> , 2021, 169, 1039-1040.	1.9	7
14	Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 989-1000.	4.2	20
15	Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2475-2483.	1.4	10
16	Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1514-1520.	1.5	11
17	Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 3255-3269.	0.9	37
18	Ductal Dilatation of ≥ 5 mm in Intraductal Papillary Mucinous Neoplasm Should Trigger the Consideration for Pancreatectomy: A Meta-Analysis and Systematic Review of Resected Cases. <i>Cancers</i> , 2021, 13, 2031.	3.7	10

#	ARTICLE	IF	CITATIONS
19	Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. <i>Surgery</i> , 2021, 169, 1093-1101.	1.9	12
20	Evidence Map of Pancreatic Surgeryâ€”A living systematic review with meta-analyses by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2021, 170, 1517-1524.	1.9	31
21	Pancreatic incidentalomas: Investigation and management. <i>Journal of Internal Medicine</i> , 2021, 290, 969-979.	6.0	6
22	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. <i>Digestive and Liver Disease</i> , 2021, 53, 998-1003.	0.9	12
23	Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2021, 21, 1371-1377.	1.1	12
24	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021, 274, 721-728.	4.2	24
25	Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. <i>Pancreatology</i> , 2021, 21, 928-937.	1.1	13
26	Dataset for the reporting of carcinoma of the exocrine pancreas: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Histopathology</i> , 2021, 79, 902-912.	2.9	18
27	Implementation of Minimally Invasive Pancreaticoduodenectomy at Low and High-Volume Centers. <i>Journal of Surgical Research</i> , 2021, 268, 720-728.	1.6	2
28	Response to the Comment on â€œPrognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelinesâ€. <i>Annals of Surgery</i> , 2021, 274, e770-e771.	4.2	2
29	Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 587-596.	1.5	46
30	ASO Author Reflections: Acceptable Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 597-598.	1.5	0
31	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	4.2	49
32	Circulating and Salivary Antibodies to <i>Fusobacterium nucleatum</i> Are Associated With Cystic Pancreatic Neoplasm Malignancy. <i>Frontiers in Immunology</i> , 2020, 11, 2003.	4.8	22
33	Global Survey on Pancreatic Surgery During the COVID-19 Pandemic. <i>Annals of Surgery</i> , 2020, 272, e87-e93.	4.2	42
34	Risk prediction for malignant intraductal papillary mucinous neoplasm of the pancreas: logistic regression versus machine learning. <i>Scientific Reports</i> , 2020, 10, 20140.	3.3	11
35	ASO Author Reflections: The Beneficial Effect of High-Volume Center Experience on Surgical Outcomes After Total Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 878-879.	1.5	2
36	ASO Author Reflections: Which Patients with Invasive Intraductal Papillary Mucinous Neoplasm Can Benefit from Adjuvant Therapy?. <i>Annals of Surgical Oncology</i> , 2020, 27, 873-874.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant Treatment in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 245.	2.8	145
38	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2020, 168, 72-84.	1.9	48
39	Dextrose-Containing Carrier Solution for Hyperthermic Intraperitoneal Chemotherapy: Increased Intraoperative Hyperglycemia and Postoperative Complications. <i>Annals of Surgical Oncology</i> , 2020, 27, 4874-4882.	1.5	7
40	The role of total pancreatectomy with islet autotransplantation in the treatment of chronic pancreatitis: A report from the International Consensus Guidelines in chronic pancreatitis. <i>Pancreatology</i> , 2020, 20, 762-771.	1.1	41
41	Multifocal/diffuse pancreatic serous cystic neoplasms: Systematic review with a new case. <i>Pancreatology</i> , 2020, 20, 902-909.	1.1	4
42	The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. <i>Annals of Surgery</i> , 2020, 271, 1-14.	4.2	294
43	Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology. <i>World Journal of Gastroenterology</i> , 2020, 26, 6822-6836.	3.3	7
44	Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. <i>Hpb</i> , 2019, 21, 219-225.	0.3	105
45	Integrated targeted metabolomic and lipidomic analysis: A novel approach to classifying early cystic precursors to invasive pancreatic cancer. <i>Scientific Reports</i> , 2019, 9, 10208.	3.3	22
46	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. <i>Cancers</i> , 2019, 11, 976.	3.7	63
47	RE: Pancreatectomy with arterial resection. <i>Hpb</i> , 2019, 21, 1254-1255.	0.3	0
48	The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma. <i>American Journal of Surgery</i> , 2019, 218, 1206-1212.	1.8	21
49	Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2019, 19, 963-970.	1.1	3
50	Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 676-689.	17.8	148
51	RE: correct reporting is of utmost importance when a controversial treatment is being evaluated. <i>Hpb</i> , 2019, 21, 1251-1252.	0.3	1
52	Use of Total Pancreatectomy and Preoperative Radiotherapy in Patients Undergoing Pancreatectomy with Artery Resection. <i>Journal of the American College of Surgeons</i> , 2019, 228, 131.	0.5	8
53	Quality of Life Following Major Laparoscopic or Open Pancreatic Resection. <i>Annals of Surgical Oncology</i> , 2019, 26, 2985-2993.	1.5	23
54	Surgical treatment of metastatic pancreatic ductal adenocarcinoma: A review of current literature. <i>Pancreatology</i> , 2019, 19, 672-680.	1.1	37

#	ARTICLE	IF	CITATIONS
55	The clinical value of ERCP-guided cholangiopancreatography using a single-operator system. <i>BMC Gastroenterology</i> , 2019, 19, 35.	2.0	4
56	Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. <i>Scientific Reports</i> , 2019, 9, 2133.	3.3	65
57	Benchmarks in Pancreatic Surgery. <i>Annals of Surgery</i> , 2019, 270, 211-218.	4.2	202
58	Response to Comment on "Main Duct Dilatation is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas". <i>Annals of Surgery</i> , 2019, 270, e109-e110.	4.2	11
59	Main pancreatic duct dilation greater than 6 mm is associated with an increased risk of high-grade dysplasia and cancer in IPMN patients. <i>Langenbeck's Archives of Surgery</i> , 2019, 404, 31-37.	1.9	15
60	Neopeptide targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer. <i>British Journal of Cancer</i> , 2019, 120, 97-108.	6.4	19
61	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). <i>Annals of Surgery</i> , 2019, 269, 10-17.	4.2	211
62	Pancreatectomies for pancreatic neoplasms in pediatric and adolescent age: A single institution experience. <i>Pancreatology</i> , 2018, 18, 204-207.	1.1	11
63	Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 1440-1447.	1.5	73
64	Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden. <i>Pancreatology</i> , 2018, 18, 900-904.	1.1	46
65	Surgical management of intraductal papillary mucinous neoplasm with main duct involvement: an international expert survey and case-vignette study. <i>Surgery</i> , 2018, 164, 17-23.	1.9	17
66	Radiological assessment of local resectability status in patients with pancreatic cancer: Interreader agreement and reader performance in two different classification systems. <i>European Journal of Radiology</i> , 2018, 106, 69-76.	2.6	5
67	Nutritional support and therapy in pancreatic surgery: A position paper of the International Study Group on Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2018, 164, 1035-1048.	1.9	165
68	Pancreatic Cystic Neoplasms: Different Types, Different Management, New Guidelines. <i>Visceral Medicine</i> , 2018, 34, 173-177.	1.3	36
69	Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses. <i>Oncotarget</i> , 2018, 9, 22451-22459.	1.8	3
70	Pancreatic MRI for the surveillance of cystic neoplasms: comparison of a short with a comprehensive imaging protocol. <i>European Radiology</i> , 2017, 27, 41-50.	4.5	51
71	Main-duct Intraductal Papillary Mucinous Neoplasm. High Cancer Risk in Duct Diameter of 5 to 9 mm. <i>Annals of Surgery</i> , 2017, 266, e86.	4.2	7
72	"Step-Up Approach" for the Treatment of Postoperative Severe Pancreatic Fistula. <i>JAMA Surgery</i> , 2017, 152, 548.	4.3	8

#	ARTICLE	IF	CITATIONS
73	Pancreatic Cystic Neoplasms: To Needle or Not To Needle, This Is the Question. American Journal of Gastroenterology, 2017, 112, 804.	0.4	1
74	Minimally Invasive Pancreaticoduodenectomy for the Treatment of Pancreatic-Head and Periampullary Tumors. JAMA Surgery, 2017, 152, 343.	4.3	5
75	The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery, 2017, 161, 584-591.	1.9	2,655
76	Preoperative biliary drainage by plastic or self-expandable metal stents in patients with periampullary tumors: results of a randomized clinical study. Endoscopy International Open, 2017, 05, E798-E808.	1.8	19
77	Bioinformatic-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. Molecular Oncology, 2017, 11, 1413-1429.	4.6	20
78	Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer. JAMA Surgery, 2017, 152, 1057.	4.3	8
79	Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience. Annals of Surgical Oncology, 2017, 24, 1120-1126.	1.5	82
80	Intraductal papillary mucinous neoplasms of the pancreas: reporting clinically relevant features. Histopathology, 2017, 70, 850-860.	2.9	10
81	Pancreatic Exocrine Insufficiency in Pancreatic Cancer. Nutrients, 2017, 9, 183.	4.1	87
82	Technical Details and Results of a Modified End-to-Side Technique of Pancreatojejunostomy: a Personal Series of 100 Patients. Journal of Gastrointestinal Surgery, 2017, 21, 2090-2099.	1.7	9
83	Diffusion-weighted MR imaging of pancreatic cancer: A comparison of mono-exponential, bi-exponential and non-Gaussian kurtosis models. European Journal of Radiology Open, 2016, 3, 79-85.	1.6	27
84	Are there still indications for total pancreatectomy?. Updates in Surgery, 2016, 68, 257-263.	2.0	59
85	The Ethical Dilemma of Compensating Living Kidney Donors. JAMA Surgery, 2016, 151, 716.	4.3	1
86	Cattell-Braasch maneuver combined with local hypothermia during superior mesenteric artery resection in pancreatectomy. Langenbeck's Archives of Surgery, 2016, 401, 1241-1247.	1.9	11
87	Microvascular Invasion in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surgery, 2016, 151, 364.	4.3	5
88	ERCP-directed radiofrequency ablation of ampullary adenomas: a knife-sparing alternative in patients unfit for surgery. Endoscopy, 2015, 47, E515-E516.	1.8	18
89	Pancreatic Cancer. Gastroenterology Research and Practice, 2015, 2015, 1-2.	1.5	2
90	Outcome of probe-based confocal laser endomicroscopy (pCLE) during endoscopic retrograde cholangiopancreatography: A single-center prospective study in 45 patients. United European Gastroenterology Journal, 2015, 3, 551-560.	3.8	23

#	ARTICLE	IF	CITATIONS
91	Pancreas-Preserving Duodenectomy Is a Safe Alternative to High-Risk Pancreatoduodenectomy for Premalignant Duodenal Lesions. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 492-497.	1.7	16
92	Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. <i>JAMA Surgery</i> , 2015, 150, 512.	4.3	83
93	Increased incidence of extrapancreatic neoplasms in patients with IPMN: Fact or fiction? A critical systematic review. <i>Pancreatology</i> , 2015, 15, 209-216.	1.1	23
94	Cattell-Braasch Maneuver Combined with Artery-First Approach for Superior Mesenteric-Portal Vein Resection During Pancreatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2015, 19, 2264-2268.	1.7	61
95	Association Between Pancreatic Intraductal Papillary Mucinous Neoplasms and Extrapancreatic Malignancies. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1162-1169.	4.4	28
96	Cystic tumors of the pancreas: Opportunities and risks. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 29.	1.0	12
97	The State of the Art of Robotic Pancreatectomy. <i>BioMed Research International</i> , 2014, 2014, 1-5.	1.9	23
98	Single-operator pancreatoscopy is helpful in the evaluation of suspected intraductal papillary mucinous neoplasms (IPMN). <i>Pancreatology</i> , 2014, 14, 510-514.	1.1	59
99	Are There Really Indications for Central Pancreatectomy?. <i>JAMA Surgery</i> , 2014, 149, 364.	4.3	6
100	Comparison of Preoperative Conference-Based Diagnosis with Histology of Cystic Tumors of the Pancreas. <i>Annals of Surgical Oncology</i> , 2014, 21, 1539-1544.	1.5	119
101	Early detection and prevention of pancreatic cancer: Is it really possible today?. <i>World Journal of Gastroenterology</i> , 2014, 20, 12118.	3.3	107
102	The use of LigaSure does not Affect Histologic Margin Assessment in Pancreatoduodenectomy (PD) specimens. <i>JOP: Journal of the Pancreas</i> , 2014, 15, 597-9.	1.5	0
103	European experts consensus statement on cystic tumours of the pancreas. <i>Digestive and Liver Disease</i> , 2013, 45, 703-711.	0.9	406
104	Enucleation of branch duct-IPMN in a transplant patient. <i>Pancreatology</i> , 2013, 13, 312-313.	1.1	5
105	Is intraductal tubulopapillary neoplasia a new entity in the spectrum of familial pancreatic cancer syndrome?. <i>Familial Cancer</i> , 2013, 13, 227-9.	1.9	12
106	Impact of body mass index for patients undergoing pancreaticoduodenectomy. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2013, 4, 37.	1.0	33
107	Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry. <i>Digestive and Liver Disease</i> , 2010, 42, 597-605.	0.9	38
108	Genetics of pancreatic cancer: where are we now? Where are we going?. <i>JOP: Journal of the Pancreas</i> , 2005, 6, 60-7.	1.5	4

#	ARTICLE	IF	CITATIONS
109	Bcl-2 expression in pancreas development and pancreatic cancer progression. Journal of Pathology, 2001, 194, 444-450.	4.5	55